PT771147E - Composições e métodos para imunidade celular tumoral in vivo melhorada - Google Patents

Composições e métodos para imunidade celular tumoral in vivo melhorada Download PDF

Info

Publication number
PT771147E
PT771147E PT95928099T PT95928099T PT771147E PT 771147 E PT771147 E PT 771147E PT 95928099 T PT95928099 T PT 95928099T PT 95928099 T PT95928099 T PT 95928099T PT 771147 E PT771147 E PT 771147E
Authority
PT
Portugal
Prior art keywords
subject
cancer
methods
vivo
compositions
Prior art date
Application number
PT95928099T
Other languages
English (en)
Inventor
Habib Fakhrai
Oliver Dorigo
Robert E Sobol
Original Assignee
Novarx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novarx Inc filed Critical Novarx Inc
Publication of PT771147E publication Critical patent/PT771147E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT95928099T 1994-07-18 1995-07-18 Composições e métodos para imunidade celular tumoral in vivo melhorada PT771147E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/276,694 US5772995A (en) 1994-07-18 1994-07-18 Compositions and methods for enhanced tumor cell immunity in vivo

Publications (1)

Publication Number Publication Date
PT771147E true PT771147E (pt) 2009-11-25

Family

ID=23057711

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95928099T PT771147E (pt) 1994-07-18 1995-07-18 Composições e métodos para imunidade celular tumoral in vivo melhorada

Country Status (10)

Country Link
US (4) US5772995A (pt)
EP (1) EP0771147B1 (pt)
JP (2) JP3839843B2 (pt)
AT (1) ATE442045T1 (pt)
CA (1) CA2195334C (pt)
DE (1) DE69535999D1 (pt)
DK (1) DK0771147T3 (pt)
ES (1) ES2334407T3 (pt)
PT (1) PT771147E (pt)
WO (1) WO1996002143A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5772995A (en) * 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
DE69834257T2 (de) * 1997-04-30 2007-01-04 Klingemann, Hans Natürliche killerzelllinien und verfahren zu ihrer verwendung
US8034332B2 (en) * 1997-04-30 2011-10-11 Conkwest, Inc. Interleukin-secreting natural killer cell lines and methods of use
EP1054683B1 (en) * 1998-02-20 2007-04-11 University Of Miami Modified heat shock protein-antigenic peptide complex
ES2226414T3 (es) 1998-06-10 2005-03-16 Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh Estimulacion del sistema inmunitario.
US6423493B1 (en) * 1998-10-26 2002-07-23 Board Of Regents The University Of Texas System Combinatorial selection of oligonucleotide aptamers
US7101543B2 (en) * 2000-03-31 2006-09-05 Novarx Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
WO2001072331A1 (en) * 2000-03-31 2001-10-04 Vaccine Chip Technology Aps Immunostimulating properties of a fragment of tgf-beta
US20030190322A1 (en) * 2000-03-31 2003-10-09 Peter Kaastrup Immunostimulating properties of a fragment of tgf-beta
ES2373431T3 (es) * 2000-03-31 2012-02-03 Novarx Células genéticamente modificadas que expresan un inhibidor de tgf-beta, siendo las células células de cáncer de pulmón.
MXPA02011093A (es) 2000-05-10 2004-08-19 David A Sirbasku Composiciones y metodos para el diagnostico, tratamiento y prevencion de canceres que responden a la hormona esteroidea.
EP2295074A1 (en) * 2001-03-07 2011-03-16 Mannkind Corporation Anti-neovasculature preparations for treating cancer
AU2002303234A1 (en) * 2001-04-02 2002-10-15 Cytoprint, Inc. Methods and apparatus for discovering, identifying and comparing biological activity mechanisms
US20030125251A1 (en) * 2001-06-21 2003-07-03 Wakefield Lalage M. Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta
US20030044393A1 (en) * 2001-07-06 2003-03-06 Annie-Chen Tran Method for increasing tumor cell immunogenicity using heat shock protein
US7247297B2 (en) * 2001-09-14 2007-07-24 The University Of Chicago Use of DF3/MUC1 regulated expression in gene therapy
US20030180301A1 (en) * 2002-01-22 2003-09-25 Shaf Keshavjee Use of TGF-beta antagonists to treat or to prevent chronic transplant rejection
AU2003304278B2 (en) * 2002-10-16 2009-03-12 Board Of Regents Of The University Of Texas System Bead bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries
JP4989850B2 (ja) * 2002-10-25 2012-08-01 アメリカ合衆国 ＴＧＦ−βの遮断により腫瘍再発を防ぐ方法
US20040115224A1 (en) * 2002-12-16 2004-06-17 Tsuneya Ohno Preparation and administration of hybrid cell vaccines for the prevention of cancer
CA2526690C (en) * 2003-05-23 2014-01-14 Board Of Regents The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting ap-1 transcription factors
JP5650367B2 (ja) * 2004-02-27 2015-01-07 アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
US20090004182A1 (en) * 2004-10-13 2009-01-01 The Ohio State University Research Foundation Methods to Treat or Prevent Viral-Associated Lymphoproliferative Disorders
EP1861123A2 (en) * 2005-02-17 2007-12-05 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Synergistic efect of tgf-beta blockade and immunogenic agents on tumors
WO2006125094A2 (en) * 2005-05-18 2006-11-23 Board Of Regents, The University Of Texas System Combinatorial selection of phosphorothioate aptamers for rnases
EP2862867A3 (en) 2005-10-25 2015-08-05 The Johns Hopkins University Methods and compositions for the treatment of Marfan syndrome and associated disorders
EP2230252A1 (en) 2006-03-13 2010-09-22 The Johns Hopkins University Augmentation of endothelial thromboresistance
ES2538265T3 (es) * 2006-10-03 2015-06-18 Genzyme Corporation Anticuerpos contra TGF-beta para uso en el tratamiento de lactantes con riesgo de desarrollar displasia broncopulmonar
PL1920781T3 (pl) * 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
AU2007347689B2 (en) 2006-12-20 2013-08-15 Novarx Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization
DK2257301T3 (da) 2008-03-03 2014-04-28 Univ Miami Immunterapi baseret på allogene cancerceller.
WO2009117116A2 (en) 2008-03-20 2009-09-24 University Of Miami Heat shock protein gp96 vaccination and methods of using same
SI2835053T1 (sl) 2010-03-12 2016-09-30 Genzyme Corporation Kombinirana terapija za zdravljenje raka dojke
CN103429732B (zh) 2010-12-27 2015-09-16 Lsip基金运营联合公司 iPS细胞及其制造方法
WO2012158866A2 (en) 2011-05-19 2012-11-22 The Johns Hopkins University Treatment of autoimmune disorders and infections using antagonists of sgk1 activity
US20140308275A1 (en) 2011-07-27 2014-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods for diagnosing and treating myhre syndrome
CA2853484C (en) 2011-10-26 2018-08-21 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
US20150037357A1 (en) * 2011-12-23 2015-02-05 Novarx Corporation Immune stimulation/metabolic inhibition as antitumor therapy
US20150044178A1 (en) 2011-12-28 2015-02-12 Kyoto Prefectural Public University Corporation Normalization of culture of corneal endothelial cells
WO2014072941A1 (en) 2012-11-09 2014-05-15 Marco Archetti Diffusible factors and cancer cells
EP3064222B1 (en) 2013-10-31 2020-10-21 Kyoto Prefectural Public University Corporation Therapeutic drug comprising tgf-beta signal inhibitor for diseases related to endoplasmic reticulum cell death in corneal endothelium
US11230719B2 (en) 2014-03-26 2022-01-25 Denovo Biopharma Llc Retroviral vector having immune-stimulating activity
ES2845727T3 (es) 2015-02-06 2021-07-27 Heat Biologics Inc Vector que coexpresa una vacuna y moléculas coestimuladoras
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination
WO2019045086A1 (ja) * 2017-08-29 2019-03-07 林化成株式会社 活性型もしくは潜在型ＴＧＦ−β１特異的抗体の用途
EP3774912A1 (en) * 2018-04-10 2021-02-17 The United States of America, as represented by the Secretary, Department of Health and Human Services Combination of near infrared photoimmunotherapy targeting cancer cells and host-immune activation
TW202134430A (zh) 2019-12-03 2021-09-16 美商紐沃進公司 腫瘤細胞疫苗

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731144A (en) * 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands
US5681562A (en) * 1991-06-25 1997-10-28 Sidney Kimmel Cancer Center Lymphokine gene therapy of cancer
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
ES2144426T3 (es) * 1991-10-25 2000-06-16 Sidney Kimmel Cancer Ct Terapia genica linfoquimica del cancer en combinacion con antigenos tumorales.
EP1160319A3 (en) 1993-04-30 2002-03-06 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH Antisense-oligonucleotides for the treatment of immunosuppressive effects of transforming growth factor-beta (TGF-beta)
DE69432375T2 (de) * 1993-04-30 2004-02-12 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Antisense Oligonukleotide zur Behandlung von immunsuppressiven Wirkungen von TGF-beta2
JPH09504786A (ja) * 1993-09-07 1997-05-13 シドニー キンメル キャンサー センター ハプロタイプ適合サイトカイン分泌細胞および免疫応答を刺激するための使用方法
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
US7101543B2 (en) * 2000-03-31 2006-09-05 Novarx Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells

Also Published As

Publication number Publication date
US20020192199A1 (en) 2002-12-19
AU711730B2 (en) 1999-10-21
EP0771147A1 (en) 1997-05-07
CA2195334C (en) 2013-03-19
AU3217895A (en) 1996-02-16
ES2334407T3 (es) 2010-03-09
EP0771147B1 (en) 2009-09-09
US8444964B2 (en) 2013-05-21
DE69535999D1 (de) 2009-10-22
US6447769B1 (en) 2002-09-10
ATE442045T1 (de) 2009-09-15
US5772995A (en) 1998-06-30
JP2006217924A (ja) 2006-08-24
DK0771147T3 (da) 2010-01-04
CA2195334A1 (en) 1996-02-01
JP3839843B2 (ja) 2006-11-01
JP2001526622A (ja) 2001-12-18
US6120763A (en) 2000-09-19
WO1996002143A1 (en) 1996-02-01
EP0771147A4 (en) 2004-06-16

Similar Documents

Publication Publication Date Title
EP0771147A4 (en) METHOD AND COMPOSITIONS FOR INCREASED TUMOR CELL IMMUNITY IN VIVO
MY116478A (en) Tri-substituted imidazoles having multiple therapeutic properties
AU693747B2 (en) Imidazo(4,5-c)pyridin-4-amines
PT1053256E (pt) Anticorpos para o receptor de morte 4 (dr4) e utilizações destes
GR3031716T3 (en) Immunogens against gonadotropin releasing hormone
CA2103458A1 (en) Method and composition to reduce myocardial reperfusion injury
PL330324A1 (en) Method of treating diarrhoea
MY114014A (en) Imidazole compounds, compositions and use
AU4959997A (en) Suppression of tnf alpha and il-12 in therapy
HU9602720D0 (en) Improved anti-dandruff shampoo
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
MX9400434A (es) Potenciamiento de temozolomida en celulas de tumores humanos.
CA2132001A1 (en) Methods of treating cancer using modified c-reactive protein
ZA200005413B (en) Cholesterol sulfate compositions for enhancement of stratum corneum function.
IL123642A0 (en) Compositions and methods of use of mononuclear phagocytes to promote axonal regeneration
AU8239298A (en) Nucleotide-comprising composition
IL116887A0 (en) Cationic copolymers of vinyl amine and vinyl alcohol for the delivery of oligonucleotides
AU3658793A (en) Bimodal molecular weight hyaluronate formulations and methods for using same
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
EP0303681A4 (en) IMMUNOSUPPRESSION IN THE TREATMENT OF PEOPLE BASED ON IMMUNOTOXIN.
IL131478A0 (en) Methods for treatment of scar tissue
HK1032360A1 (en) Combination therapy for the treatment of tumors.
IL127851A0 (en) Inhibition of TNF activity
GB9426012D0 (en) Mobilisation of haematopoietic cells
NZ316609A (en) Lyophilized thioxanthenone antitumor agents